Synthesis, Anticancer and Antibacterial Activity of Betulinic and Betulonic Acid C-28-Triphenylphosphonium Conjugates with Variable Alkyl Linker Length.
Conjugation of triterpenoids such as betulinic acid 1 with Triphenylphosphonium (TPP) group is a powerful approach to generating medicinal compounds. Their development proposes structure optimization in respect of availability and activity towards target cells and organelles. Selection of 1 or its precursor betulonic acid 2 and the optimal linker is of particular importance for drug candidate identification among the TPP-triterpenoid conjugates. In this study new C-28-TPP conjugated derivatives of 1 and 2 with the alkyl/alkoxyalkyl linkers of variable length were synthesized and compared regarding their anticancer, antibacterial, and mitochondria-targeted effects. The TPP conjugates of 1 and 2 [6a-f, 7a-f] were synthesized by the reaction of halogenalkyl esters [3a-f, 4a-f, 5] with triphenylphosphine in acetonitrile upon heating. Cytotoxicity (MTT assay), antibacterial activity (microdilution assay) and mitochondrial effects (flow cytofluorometry) were studied. Conjugation with the TPP group greatly increased cytotoxicity of the triterpenoids up to 30 times. The conjugates were up to 10-17 times more active against MCF-7 (IC50 = 0.17µM, 72h, 6c) and PC-3 (IC50 = 0.14µM, 72h, 6a) cancer cells than for human skin fibroblasts. Enhanced antibacterial (bactericidal) activity of the TPP-triterpenoid conjugates with MIC for Gram-positive bacteria as low as 2µM (6a, 7a) was for the first time revealed. The conjugates were found to effectively inhibit oxidation of 2',7'-dichlorofluorescin probe in cytosol, decrease transmembrane potential and increase superoxide radical level in mitochondria. Relationships between the effects and structure of the TPP-triterpenoid conjugates were evaluated and are discussed. Based on the results, 6a can be selected for further preclinical investigation as a potential anticancer compound.